| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WASHINGTON—Leading scientists, public policy experts and biotech industry leaders joined forces recently to launch Working to Fight AMR, a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance (AMR)—it will also advocate for policies that catalyze the creation of new medicines.
 
“Antimicrobial resistance already poses a grave threat to human health, and it is a looming public health emergency," said Dr. Greg Frank, director of infectious disease policy at the Biotechnology Innovation Organization, who is heading up the coalition. "Working to Fight AMR will advocate for policies that create a sustainable ecosystem and boost investment in this deeply neglected area.”
 
Scientists have developed only one truly novel antibiotic since 1984. For most companies, investing in AMR research does not make sense, as new treatments would be used sparingly. Companies risk not generating enough revenue to recoup development costs. Globally, just 1 percent of experimental medicines aim to fight bacterial infections.
 
“We're eager to mobilize this diverse community of stakeholders, including patients, to implement practical policy solutions to combat superbugs,” Frank added. “Together, we can save millions of lives.”

Related Topics

Published In

Volume 15 - Issue 10 | October 2019

October 2019

October 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue